33 studies found for:    "familial hemophagocytic lymphohistiocytosis"
Show Display Options
Rank Status Study
21 Active, not recruiting Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)
Conditions: Hemophagocytic Lymphohistiocytosis;   Chronic Active Epstein-Barr Virus Infection;   Chronic Granulomatous Disease;   HIGM-1;   Leukocyte Adhesion Deficiency;   IPEX
Intervention: Biological: Hematopoietic Stem Cell Transplant
22 Active, not recruiting Children and Adult Hemophagocytic Syndrome (HLHa)
Condition: Hemophagocytic Syndrome
Intervention: Biological: Identification of biological markers
23 Recruiting CD34+ Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation for Non-Malignant Disease
Conditions: Bone Marrow Failure Syndrome;   Severe Aplastic Anemia;   Severe Congenital Neutropenia;   Amegakaryocytic Thrombocytopenia;   Diamond-Blackfan Anemia;   Schwachman Diamond Syndrome;   Primary Immunodeficiency Syndromes;   Acquired Immunodeficiency Syndromes;   Histiocytic Syndrome;   Familial Hemophagocytic Lymphocytosis;   Lymphohistiocytosis;   Macrophage Activation Syndrome;   Langerhans Cell Histiocytosis (LCH);   Hemoglobinopathies;   Sickle Cell Disease;   Sickle Cell-beta-thalassemia
Intervention: Biological: CD34 Stem Cell Selection Therapy
24 Active, not recruiting Stem Cell Transplant for Immunologic or Histiocytic Disorders
Conditions: Hemophagocytic Lymphohistiocytosis;   X-Linked Lymphoproliferative Disorders;   Chediak-Higashi Syndrome;   Griscelli Syndrome;   Immunologic Deficiency Syndromes;   Langerhans-Cell Histiocytosis
Interventions: Procedure: Stem Cell Transplant;   Drug: Fludarabine, melphalan, ATG or Campath
25 Active, not recruiting
Has Results
T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
Conditions: Hemophagocytic Lymphohistiocytosis;   X-Linked Lymphoproliferative Disorders;   Chediak-Higashi Syndrome;   Griscelli Syndrome;   Immunologic Diseases;   Langerhans-Cell Histiocytosis;   Hematologic Diseases
Interventions: Procedure: Stem Cell Transplant;   Drug: Myeloablative conditioning regimen
26 Recruiting BMT Abatacept for Non-Malignant Diseases
Conditions: Hurler Syndrome;   Fanconi Anemia;   Glanzmann Thrombasthenia;   Wiskott-Aldrich Syndrome;   Chronic Granulomatous Disease;   Severe Congenital Neutropenia;   Leukocyte Adhesion Deficiency;   Shwachman-Diamond Syndrome;   Diamond-Blackfan Anemia;   Dyskeratosis-congenita;   Chediak-Higashi Syndrome;   Severe Aplastic Anemia;   Thalassemia Major;   Hemophagocytic Lymphohistiocytosis;   Sickle Cell Disease
Intervention: Drug: Abatacept
27 Recruiting Immune Disorder HSCT Protocol
Conditions: Immune Deficiency Disorders;   Severe Combined Immunodeficiency;   Chronic Granulomatous Disease;   X-linked Agammaglobulinemia;   Wiskott-Aldrich Syndrome;   Hyper-IgM;   DiGeorge Syndrome;   Chediak-Higashi Syndrome;   Common Variable Immune Deficiency;   Immune Dysregulatory Disorders;   Hemophagocytic Lymphohistiocytosis;   IPEX;   Autoimmune Lymphoproliferative Syndrome;   X-linked Lymphoproliferative Syndrome
Intervention: Drug: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
28 Recruiting Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
Conditions: SCID;   Omenn's Syndrome;   Reticular Dysgenesis;   Wiskott-Aldrich Syndrome;   Bare Lymphocyte Syndrome;   Common Variable Immunodeficiency;   Chronic Granulomatous Disease;   CD40 Ligand Deficiency;   Hyper IgM Syndrome;   X-linked Lymphoproliferative Disease;   Hemophagocytic Lymphohistiocytosis;   Griscelli Syndrome;   Chediak-Higashi Syndrome;   Langerhan's Cell Histiocytosis
Interventions: Drug: Alemtuzumab 0.3 mg;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Stem Cell Transplantation;   Drug: Fludarabine phosphate 40 mg;   Drug: Melphalan;   Drug: Alemtuzumab 0.2 mg;   Drug: Fludarabine phosphate 30 mg;   Drug: MESNA
29 Completed Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma
Conditions: Lymphoma;   Nonneoplastic Condition
Interventions: Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: in situ hybridization;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: western blotting;   Other: flow cytometry;   Other: immunohistochemistry staining method;   Other: medical chart review
30 Active, not recruiting CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene
Conditions: Acute Lymphoblastic Leukemia;   Non-Hodgkin's Lymphoma;   Myelodysplastic Syndrome;   Chronic Myeloid Leukemia
Intervention: Biological: Allodepleted T Cells
31 Recruiting Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders
Condition: Non-Malignant
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
32 Recruiting CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Conditions: Chronic Myeloid Leukemia (CML);   Acute Myelogenous Leukemia (AML);;   Myelodysplastic Syndrome (MDS);;   Juvenile Myelomonocytic Leukemia (JMML);;   Acute Lymphoblastic Leukemia (ALL);;   Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions: Device: CliniMACS CD34+ Reagent System;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Alemtuzumab;   Drug: Tacrolimus;   Drug: Melphalan;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Methylprednisolone
33 Recruiting Reduced Intensity Conditioning in Patients Aged ≤35 With Non-Malignant Disorders Undergoing UCBT, BMT, or PBSCT
Conditions: Primary Immunodeficiency Syndromes;   Congenital Bone Marrow Failure Syndromes;   Inherited Metabolic Disorders (IMD);   Hereditary Anemias;   Patients With Sickle Disease Presenting Specific Symptoms
Interventions: Drug: Hydroxyurea;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-33) Next Page   
Study has passed its completion date and status has not been verified in more than two years.